Zhi Zhou1, Martijn L T M Müller1, Prabesh Kanel1, Jason Chua1, Vikas Kotagal1, Daniel I Kaufer1, Roger L Albin1, Kirk A Frey1, Nicolaas I Bohnen2. 1. From the Department of Radiology (Z.Z., M.L.T.M.M., P.K., K.A.F., N.I.B.), Morris K. Udall Center of Excellence for Parkinson's Disease Research (M.L.T.M.M., P.K., R.L.A., N.I.B.), and Department of Neurology (J.C., V.K., K.A.F., R.L.A., N.I.B.), University of Michigan, Ann Arbor; Department of Geriatrics (Z.Z.), China Japan Friendship Hospital, Beijing, China; Neurology Service and Geriatric Research, Education, and Clinical Center (V.K., R.L.A., N.I.B.), VA Ann Arbor Healthcare System, MI; and Department of Neurology (D.I.K.), University of North Carolina, Chapel Hill. 2. From the Department of Radiology (Z.Z., M.L.T.M.M., P.K., K.A.F., N.I.B.), Morris K. Udall Center of Excellence for Parkinson's Disease Research (M.L.T.M.M., P.K., R.L.A., N.I.B.), and Department of Neurology (J.C., V.K., K.A.F., R.L.A., N.I.B.), University of Michigan, Ann Arbor; Department of Geriatrics (Z.Z.), China Japan Friendship Hospital, Beijing, China; Neurology Service and Geriatric Research, Education, and Clinical Center (V.K., R.L.A., N.I.B.), VA Ann Arbor Healthcare System, MI; and Department of Neurology (D.I.K.), University of North Carolina, Chapel Hill. nbohnen@umich.edu.
Abstract
OBJECTIVE: To determine whether β-amyloidopathy correlates with apathy rating scores independently of mood changes and other neurodegenerative processes in Parkinson disease (PD). METHODS: In this cross-sectional study, patients with PD (n = 64, 48 male and 16 female, mean age 69.2 ± 6.7 years, Hoehn & Yahr stage 2.7 ± 0.5, Montreal Cognitive Assessment score 25.3 ± 3.0) underwent [11C]Pittsburgh compound B β-amyloid, [11C]dihydrotetrabenazine vesicular monoamine transporter type 2 (VMAT2), and [11C]methyl 4 piperidinyl propionate acetylcholinesterase brain PET imaging and clinical assessments, including the Marin Apathy Evaluation Scale, Clinician Version. Patients were recruited on the basis of having at least 1 risk factor for PD dementia, but they were excluded if they had dementia. RESULTS: Mean apathy rating score was 25.4 ± 6.4, reflecting predominantly subclinical apathy. Apathy rating scale scores correlated with amyloid binding, cognitive, depressive, and anxiety scores but not significantly with age, duration of disease, striatal VMAT2, or cholinergic binding. Multiple regression analysis model (p < 0.0001) showed significant regressor effects for global β-amyloid burden (p = 0.0038) with significant covariate effects for global cognitive z scores (p = 0.028) and for anxiety (p = 0.038) but not with depressive scores. Voxel-based analysis showed robust correlation between apathy rating scale scores and β-amyloid binding in bilateral nuclei accumbens, inferior frontal, and cingulate cortices (family-wise error rate-corrected p < 0.005). CONCLUSION: Apathy is independently associated with β-amyloidopathy in patients with PD at risk of dementia. Regional brain findings are most robust for β-amyloidopathy in the nuclei accumbens, inferior frontal, and cingulate regions. Findings may provide an explanation for the often treatment-refractory nature of apathy in advancing PD despite optimized dopaminergic and antidepressant pharmacotherapy. CLINICALTRIALSGOV IDENTIFIER: NCT01565473.
OBJECTIVE: To determine whether β-amyloidopathy correlates with apathy rating scores independently of mood changes and other neurodegenerative processes in Parkinson disease (PD). METHODS: In this cross-sectional study, patients with PD (n = 64, 48 male and 16 female, mean age 69.2 ± 6.7 years, Hoehn & Yahr stage 2.7 ± 0.5, Montreal Cognitive Assessment score 25.3 ± 3.0) underwent [11C]Pittsburgh compound B β-amyloid, [11C]dihydrotetrabenazine vesicular monoamine transporter type 2 (VMAT2), and [11C]methyl 4 piperidinyl propionate acetylcholinesterase brain PET imaging and clinical assessments, including the Marin Apathy Evaluation Scale, Clinician Version. Patients were recruited on the basis of having at least 1 risk factor for PD dementia, but they were excluded if they had dementia. RESULTS: Mean apathy rating score was 25.4 ± 6.4, reflecting predominantly subclinical apathy. Apathy rating scale scores correlated with amyloid binding, cognitive, depressive, and anxiety scores but not significantly with age, duration of disease, striatal VMAT2, or cholinergic binding. Multiple regression analysis model (p < 0.0001) showed significant regressor effects for global β-amyloid burden (p = 0.0038) with significant covariate effects for global cognitive z scores (p = 0.028) and for anxiety (p = 0.038) but not with depressive scores. Voxel-based analysis showed robust correlation between apathy rating scale scores and β-amyloid binding in bilateral nuclei accumbens, inferior frontal, and cingulate cortices (family-wise error rate-corrected p < 0.005). CONCLUSION: Apathy is independently associated with β-amyloidopathy in patients with PD at risk of dementia. Regional brain findings are most robust for β-amyloidopathy in the nuclei accumbens, inferior frontal, and cingulate regions. Findings may provide an explanation for the often treatment-refractory nature of apathy in advancing PD despite optimized dopaminergic and antidepressant pharmacotherapy. CLINICALTRIALSGOV IDENTIFIER: NCT01565473.
Authors: Ziad S Nasreddine; Natalie A Phillips; Valérie Bédirian; Simon Charbonneau; Victor Whitehead; Isabelle Collin; Jeffrey L Cummings; Howard Chertkow Journal: J Am Geriatr Soc Date: 2005-04 Impact factor: 5.562
Authors: Xia Shao; Raphaël Hoareau; Brian G Hockley; Louis J M Tluczek; Bradford D Henderson; Henry C Padgett; Peter J H Scott Journal: J Labelled Comp Radiopharm Date: 2011-05-30 Impact factor: 1.921
Authors: Myria Petrou; Nicolaas I Bohnen; Martijn L T M Müller; Robert A Koeppe; Roger L Albin; Kirk A Frey Journal: Neurology Date: 2012-08-29 Impact factor: 9.910
Authors: Christopher G Goetz; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Glenn T Stebbins; Matthew B Stern; Barbara C Tilley; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J Van Hilten; Nancy LaPelle Journal: Mov Disord Date: 2007-01 Impact factor: 10.338
Authors: Murat Emre; Dag Aarsland; Richard Brown; David J Burn; Charles Duyckaerts; Yoshikino Mizuno; Gerald Anthony Broe; Jeffrey Cummings; Dennis W Dickson; Serge Gauthier; Jennifer Goldman; Christopher Goetz; Amos Korczyn; Andrew Lees; Richard Levy; Irene Litvan; Ian McKeith; Warren Olanow; Werner Poewe; Niall Quinn; Christina Sampaio; Eduardo Tolosa; Bruno Dubois Journal: Mov Disord Date: 2007-09-15 Impact factor: 10.338
Authors: Mirnova E Ceïde; Daniel Eguchi; Emmeline I Ayers; David W Lounsbury; Joe Verghese Journal: Int J Environ Res Public Health Date: 2022-06-16 Impact factor: 4.614
Authors: Philippe Robert; Claire Albrengues; Roxane Fabre; Alexandre Derreumaux; Marie Pierre Pancrazi; Isabelle Luporsi; Bruno Dubois; Stéphane Epelbaum; Grégoire Mercier; Pierre Foulon; François Bremond; Valeria Manera Journal: Alzheimers Dement (N Y) Date: 2021-05-11